Dabigatran je organsko jedinjenje, koje sadrži 34 atoma ugljenika i ima molekulsku masu od 627,733 -{Da}-.-{Bauer KA: New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;}--{Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. . Epub 2009 Aug 30. }--{Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. }--{Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. . Epub 2008 Apr 14. }--{Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. }--{Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. }--{Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. }--{Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarinalone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. . Epub 2007 Aug 17. }--{Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. }--{Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 15;}--{European Medicines Agency:http://www.ema.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en6.pdf }--{. pharmscope:http://www.pharmscope.com/ptjournal/fulltext/32/5/PTJ3205271.pdf }--{Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. .. }- Osobine
Osobina Vrednost Broj akceptora vodonika 10 Broj donora vodonika 2 Broj rotacionih veza 17 Particioni koeficijent (-{ALogP)}- 5,8 Rastvorljivost (-{logS, log(mol/L}-)) -9,2 Polarna površina (-{PSA}-, Å2) 154,0
Reference
Literatura
Spoljašnje veze
-{Dabigatran}-
Категорија:Антикоагуланси Категорија:Антитромботички агенси Категорија:Карбоксилатни естри Категорија:Ацетамиди Категорија:Етри Категорија:Ароматични амини Категорија:Пиридини Категорија:Бензимидазоли